Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15114430,plasma AUC,MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h).,Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114430/),[pM] / [h·l],123,57921,DB00764,Mometasone
,15114430,plasma AUC,MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h).,Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114430/),[pM] / [h·l],112,57922,DB00764,Mometasone
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],100.3,95830,DB00764,Mometasone
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],181.0,95831,DB00764,Mometasone
,25740265,Cmax,"Caucasian subjects for Cmax were 1.23 (1.11 - 1.38) and 1.24 (1.11 - 1.38) for indacaterol and MF, respectively.","Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740265/),,1.23,100066,DB00764,Mometasone
,25740265,Cmax,"Caucasian subjects for Cmax were 1.23 (1.11 - 1.38) and 1.24 (1.11 - 1.38) for indacaterol and MF, respectively.","Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740265/),,1.24,100067,DB00764,Mometasone
,25740265,maximum ratios,"For AUC, the maximum ratios were 1.22 (1.09 - 1.36) and 1.30 (1.18 - 1.44) for indacaterol and MF, respectively.","Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740265/),,1,100068,DB00764,Mometasone
,27310329,Relative bioavailability,"Relative bioavailability of indacaterol and MF for inhalation with versus without charcoal, based on AUClast, was 0.25 (90% confidence interval [CI], 0.18-0.35) and 0.70 (90%CI, 0.52-0.93), respectively.",Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310329/),,0.25,133501,DB00764,Mometasone
,27310329,Relative bioavailability,"Relative bioavailability of indacaterol and MF for inhalation with versus without charcoal, based on AUClast, was 0.25 (90% confidence interval [CI], 0.18-0.35) and 0.70 (90%CI, 0.52-0.93), respectively.",Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310329/),,0.70,133502,DB00764,Mometasone
,17523699,clearance rate,"The clearance rate of des-ciclesonide is very high (228 L/h), increasing its safety profile by utilizing extra-hepatic clearance mechanisms.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),[l] / [h],228,142575,DB00764,Mometasone
,17523699,protein binding fraction,Both des-ciclesonide and mometasone have a high protein binding fraction (98-99%).,Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),%,98-99,142576,DB00764,Mometasone
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,332,142577,DB00764,Mometasone
,17523699,Vd,"The volume of distribution (Vd) is proportional to the lipophilicity of the drug, with the Vd of fluticasone being 332L compared with 183L for budesonide.",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),l,183,142578,DB00764,Mometasone
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,1800,142579,DB00764,Mometasone
,17523699,receptor binding,"Among the ICS, fluticasone and mometasone have the highest receptor binding affinity (1800 and 2200, respectively), followed by budesonide at 935 (relative to dexamethasone = 100).",Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523699/),,2200,142580,DB00764,Mometasone
,11075308,half-life (t1/2),The half-life (t1/2) following i.v. administration was 4.5 hours.,Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11075308/),h,4.5,167896,DB00764,Mometasone
less,11075308,systemic bioavailability,"In contrast, following DPI administration, plasma MF concentrations were below the limit of quantification (LOQ, 50 pg/mL) for many subjects (10 of 24), and the systemic bioavailability by this route was estimated to be less than 1%.",Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11075308/),%,1,167897,DB00764,Mometasone
,11192139,ratio of peripheral to central lung deposition,The mean (+/- SD) ratio of peripheral to central lung deposition was 0.8+/-0.2.,Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192139/),,0.8,188357,DB00764,Mometasone
,32967685,trough FEV1,Both indacaterol salts demonstrated statistically significant improvements in trough FEV1 of 186 mL (maleate) and 146 mL (acetate) compared with placebo (both P < 0.001).,"Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32967685/),ml,186,208693,DB00764,Mometasone
,32967685,trough FEV1,Both indacaterol salts demonstrated statistically significant improvements in trough FEV1 of 186 mL (maleate) and 146 mL (acetate) compared with placebo (both P < 0.001).,"Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32967685/),ml,146,208694,DB00764,Mometasone
,32967685,AUC0-4h,"FEV1 AUC0-4h improved by 248 mL (maleate) and 245 mL (acetate), and PEF by 33 L/min (maleate) and 30.8 L/min (acetate) versus placebo.","Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32967685/),ml,248,208695,DB00764,Mometasone
,32967685,AUC0-4h,"FEV1 AUC0-4h improved by 248 mL (maleate) and 245 mL (acetate), and PEF by 33 L/min (maleate) and 30.8 L/min (acetate) versus placebo.","Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32967685/),ml,245,208696,DB00764,Mometasone
,32940181,encap,"The encapsulation efficiency of the microspheres loaded with mometasone furoate was in the range of 53.1% to 95.2%, and the encapsulation efficiency of the microspheres could be greatly affected by the proportion of oil phase to the water phase and other formulation parameters.",Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32940181/),%,53.1,209477,DB00764,Mometasone
,32940181,encap,"The encapsulation efficiency of the microspheres loaded with mometasone furoate was in the range of 53.1% to 95.2%, and the encapsulation efficiency of the microspheres could be greatly affected by the proportion of oil phase to the water phase and other formulation parameters.",Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32940181/),%,95,209478,DB00764,Mometasone
,22353786,water content,"The purpose of the investigation presented here was to determine the noninferiority of a topical mometasone formulation, a light cream (O/W 60/40 emulsion) with mometasone furoate 0.1% (water content of 33%) versus marketed comparators.","Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22353786/),%,33,248294,DB00764,Mometasone
,22353786,bioavailability,"Thus, the topical bioavailability of the active ingredient mometasone furoate (0.1%) was regarded to be similar for Mometasone cream and the mometasone comparator.","Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22353786/),%,0.1,248295,DB00764,Mometasone
